BIOARCTIC AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 240.2 SEK | -1.15% |
|
+8.79% | -10.31% |
| May. 29 | Nordic Stocks Dropped Wednesday; NEL Fell Furthest | DJ |
| May. 27 | Nordic Shares Moved Upward Monday; Sinch Led Increases | DJ |
| Sales 2024 * | 535M 51.54M | Sales 2025 * | 1.04B 100M | Capitalization | 21.22B 2.04B |
|---|---|---|---|---|---|
| Net income 2024 * | 34M 3.27M | Net income 2025 * | 433M 41.68M | EV / Sales 2024 * | 37.9 x |
| Net cash position 2024 * | 946M 91.04M | Net cash position 2025 * | 1.21B 116M | EV / Sales 2025 * | 19.2 x |
| P/E ratio 2024 * |
638
x | P/E ratio 2025 * |
49
x | Employees | 90 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 44.2% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioArctic AB
More press releases
More news
| 1 day | -1.15% | ||
| 1 week | +8.79% | ||
| Current month | -0.99% | ||
| 1 month | +24.07% | ||
| 3 months | +13.95% | ||
| 6 months | +0.59% | ||
| Current year | -10.31% |
1 week
223.20
250.00
1 month
189.90250.00
Current year
175.00288.40
1 year
175.00392.00
3 years
66.70392.00
5 years
47.00392.00
10 years
20.40392.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 12-12-31 | |
| Founder | 77 | 03-01-23 | |
| Founder | 75 | 03-01-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eugen Steiner
CHM | Chairman | 70 | 16-12-31 |
| Director/Board Member | 58 | 23-05-31 | |
| Director/Board Member | 56 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.25% | 5 M€ | +17.05% | ||
| 0.89% | 14 M€ | -4.50% | ||
| 0.25% | 142 M€ | +12.57% | - | |
| 0.19% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 240.2 | -1.15% | 64,209 |
| 24-06-04 | 243 | -1.78% | 86,145 |
| 24-06-03 | 247.4 | +1.98% | 166,067 |
| 24-05-31 | 242.6 | +7.35% | 732,004 |
| 24-05-30 | 226 | +2.36% | 99,781 |
Delayed Quote Nasdaq Stockholm, June 05, 2024 at 11:29 am EDT
More quotes
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
Calendar
2024-08-29
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
240.2
SEK
Average target price
368
SEK
Spread / Average Target
+53.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.31% | 2.05B | |
| +55.70% | 55.7B | |
| +41.08% | 39.91B | |
| -5.39% | 39.57B | |
| -5.56% | 28.16B | |
| +16.46% | 26.3B | |
| -20.56% | 18.94B | |
| +33.03% | 12.17B | |
| +25.85% | 12.12B | |
| +2.72% | 12.12B |
- Stock Market
- Equities
- BIOA B Stock
